GENE ONLINE|News &
Opinion
Blog

ASCO 2024
ASCO Breakthrough 2024: Key Advances in the NSCLC Landscape with First-line Treatment Selpercatinib Trial Updates
2024-08-08
ASCO Breakthrough 2024: Radiation Alone Works as Well as Chemoradiation for Low-Risk Nasopharyngeal Cancer
2024-08-08
New Research Highlights Potential for Surgery-Free Management of Esophageal Cancer at ASCO Breakthrough 2024
2024-08-08
Merck Buys EyeBio for $3B and Shares Global Policy Perspectives During BIO in San Diego
2024-06-20
Johnson & Johnson’s Bispecific Antibodies for Atopic Dermatitis and Talks of Biotech Partnerships at BIO 2024
2024-06-20
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
2024-06-19
ASCO 2024: Covering Skin Cancer, Bispecific Antibody Treatment, TIGIT-Targeted Drugs, Radiotherapy and More
2024-05-29
Major Cancer Research Publications at the 2024 American Society of Clinical Oncology Annual Meeting
2024-05-28
LATEST
Bio Asia Pacific 2024 Close ASEAN Collaborations: Catalyzing Innovation and Global Partnerships
2024-09-12
Illumina’s IVD Biomarker Test Becomes the First FDA-approved Pan-cancer Companion Diagnostics Kit
2024-09-11
Lotus Pharma Expands in Southeast Asia with Alpha Choay Acquisition from Sanofi
2024-09-06
Indian CDMO Stocks in the Spotlight: US House to Vote on BIOSECURE Act Next Week
2024-09-06
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
Illumina Wins EU Court Battle, Dodges Fine, but Grail Deal Already Void
2024-09-05
Breaking New Ground for Clinical Trials with AI/ML Applications
2024-09-05
EVENT
2024-09-13
ESMO Congress 2024
Barcelona, Spain
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
Scroll to Top